Global Anti-Obesity Drugs Market is expected to reach US$ XX Mn by 2026 from US$ XX Mn in 2019, at a
CAGR of 15.1% during the forecast period.
Global Anti-Obesity Drugs Market Overview:
Anti-obesity drugs are medications, which are used to reduce body weight by lowering cholesterol levels
in the body. These drugs affect the human body's basic functions by modifying appetite or eating
Global Anti-Obesity Drugs Market Dynamics:
The rising prevalence of obesity worldwide is the major factor driving the market growth.
The anti-obesity drugs market is expected to rise due to the rising cases of obesity and overweight
among patients worldwide as a result of inactive lifestyles and bad eating habits. The World Health
Organization (WHO) estimates that over 1.8 billion adults aged 18 and above were overweight in 2016.
The leading players in the industry are also undergoing product creation and finding market approvals as
a result of the rise in the global obesity population. In 2018, Novo Nordisk formed an alliance with
Evotec AG to discover and produce drug molecules to treat a variety of metabolic disorders, such as
obesity, diabetes, and other related illnesses. The increasing need for medicines that have long-term
effects is expected to create enormous opportunities for market vendors to develop new products. This
factor is expected to eventually aid the market growth.
The rising prevalence of obesity, as well as type II diabetes, has prompted many market analysts and
vendors to conduct studies on drugs that can treat both obesity and type II diabetes. MED10382 by
AstraZeneca and Bimagrumab by Novartis are two of the medicines being tested for obesity and type II
However, drug side effects and the lack of combination therapy are expected to limit the market's
growth. Along with this, the market for anti-obesity drugs is expected to be hampered by the rising
acceptance of alternative alternatives such as gyms, exercise spas, treatments to minimise obesity,